BACKGROUND: Promoter hypermethylation and global hypomethylation in the human genome are hallmarks of most cancers. Detection of aberrant methylation in white blood cells (WBC) has been suggested as a marker for cancer development, but has not been extensively investigated. This study was carried out to determine whether aberrant methylation in WBC DNA can be used as a surrogate biomarker for breast cancer risk. PATIENTS AND METHODS: Promoter hypermethylation of 8 tumor suppressor genes (RASSF1A, APC, HIN1, BRCA1, CYCLIND2, RARbeta, CDH1 and TWIST1) and DNA methylation for three repetitive elements (LINE1, Sat2 and Alu) were analyzed in invasive ductal carcinoma of the breast, paired adjacent normal tissue and WBC from 40 breast cancer patients by the MethyLight assay. Methylation in WBC from 40 controls was also analyzed. RESULTS: Tumor and adjacent tissues showed frequent hypermethylation for all genes tested, while WBC DNA was rarely hypermethylated. For HIN1, RASSF1A, APC and TWIST1, there was agreement between hypermethylation in tumor and adjacent tissues (p=0.04, p=0.02, p=0.005 and p<0.0001, respectively). DNA methylation for the three repetitive elements was lower in tumor compared to adjacent tissue and WBC DNA. Significant correlations in the methylation of Sat2M1 between tumor and adjacent tissues and WBC DNA were found (p<0.0001 and p=0.046, respectively). There was also a significant difference in methylation of Sat2M1 between cases and controls (p=0.01). CONCLUSION: These results suggest that further studies of WBC methylation, including prospective studies, may provide biomarkers of breast cancer risk.
BACKGROUND: Promoter hypermethylation and global hypomethylation in the human genome are hallmarks of most cancers. Detection of aberrant methylation in white blood cells (WBC) has been suggested as a marker for cancer development, but has not been extensively investigated. This study was carried out to determine whether aberrant methylation in WBC DNA can be used as a surrogate biomarker for breast cancer risk. PATIENTS AND METHODS: Promoter hypermethylation of 8 tumor suppressor genes (RASSF1A, APC, HIN1, BRCA1, CYCLIND2, RARbeta, CDH1 and TWIST1) and DNA methylation for three repetitive elements (LINE1, Sat2 and Alu) were analyzed in invasive ductal carcinoma of the breast, paired adjacent normal tissue and WBC from 40 breast cancerpatients by the MethyLight assay. Methylation in WBC from 40 controls was also analyzed. RESULTS:Tumor and adjacent tissues showed frequent hypermethylation for all genes tested, while WBC DNA was rarely hypermethylated. For HIN1, RASSF1A, APC and TWIST1, there was agreement between hypermethylation in tumor and adjacent tissues (p=0.04, p=0.02, p=0.005 and p<0.0001, respectively). DNA methylation for the three repetitive elements was lower in tumor compared to adjacent tissue and WBC DNA. Significant correlations in the methylation of Sat2M1 between tumor and adjacent tissues and WBC DNA were found (p<0.0001 and p=0.046, respectively). There was also a significant difference in methylation of Sat2M1 between cases and controls (p=0.01). CONCLUSION: These results suggest that further studies of WBC methylation, including prospective studies, may provide biomarkers of breast cancer risk.
Authors: François Gaudet; J Graeme Hodgson; Amir Eden; Laurie Jackson-Grusby; Jessica Dausman; Joe W Gray; Heinrich Leonhardt; Rudolf Jaenisch Journal: Science Date: 2003-04-18 Impact factor: 47.728
Authors: M Widschwendter; J Berger; M Hermann; H M Müller; A Amberger; M Zeschnigk; A Widschwendter; B Abendstein; A G Zeimet; G Daxenbichler; C Marth Journal: J Natl Cancer Inst Date: 2000-05-17 Impact factor: 13.506
Authors: Ji-Yeob Choi; Smitha R James; Petra A Link; Susan E McCann; Chi-Chen Hong; Warren Davis; Mary K Nesline; Christine B Ambrosone; Adam R Karpf Journal: Carcinogenesis Date: 2009-07-07 Impact factor: 4.944
Authors: Cameron Snell; Michael Krypuy; Ee Ming Wong; Maurice B Loughrey; Alexander Dobrovic Journal: Breast Cancer Res Date: 2008-02-12 Impact factor: 6.466
Authors: Alexandra J White; Jia Chen; Lauren E McCullough; Xinran Xu; Yoon Hee Cho; Susan L Teitelbaum; Alfred I Neugut; Mary Beth Terry; Hanina Hibshoosh; Regina M Santella; Marilie D Gammon Journal: Cancer Causes Control Date: 2015-09-25 Impact factor: 2.506
Authors: Adana A M Llanos; Catalin Marian; Theodore M Brasky; Ramona G Dumitrescu; Zhenhua Liu; Joel B Mason; Kepher H Makambi; Scott L Spear; Bhaskar V S Kallakury; Jo L Freudenheim; Peter G Shields Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: Xinran Xu; Marilie D Gammon; Hector Hernandez-Vargas; Zdenko Herceg; James G Wetmur; Susan L Teitelbaum; Patrick T Bradshaw; Alfred I Neugut; Regina M Santella; Jia Chen Journal: FASEB J Date: 2012-02-27 Impact factor: 5.191
Authors: Julia Mendoza-Pérez; Jian Gu; Luis A Herrera; Nizar M Tannir; Surena F Matin; Jose A Karam; Maosheng Huang; David W Chang; Christopher G Wood; Xifeng Wu Journal: Clin Cancer Res Date: 2015-12-11 Impact factor: 12.531
Authors: Kathryn Hughes Barry; Lee E Moore; Linda M Liao; Wen-Yi Huang; Gabriella Andreotti; Matthew Poulin; Sonja I Berndt Journal: Prostate Date: 2015-08-07 Impact factor: 4.104